Core Viewpoint - The case highlights the illegal excavation of ancient cultural sites and tombs, leading to significant legal consequences for the perpetrators involved in the crime [1][4]. Group 1: Discovery and Initial Actions - The criminal activities began when an individual discovered suspicious holes in a cornfield while fishing, leading to a plan to excavate for valuable artifacts [2]. - The group, led by Wang, organized a team to excavate the site, purchasing tools like the Luoyang shovel and probe to facilitate their illegal activities [3]. Group 2: Criminal Activities and Network Formation - The group initially found low-value artifacts but continued to excavate in various locations, ultimately forming a network for the illegal trade of stolen cultural relics [3]. - Despite multiple excavations, the group only profited approximately 20,000 yuan, contrasting sharply with the irreversible damage caused to cultural heritage sites [3]. Group 3: Evidence Collection and Legal Proceedings - The investigation involved comprehensive evidence collection, including on-site inspections and the use of drones to map the locations of the excavated sites [4]. - The case was complicated by the number of excavations and the covert nature of the activities, necessitating further investigation to solidify the evidence chain [5]. Group 4: Judicial Outcomes - The court sentenced the main perpetrator, Wang, to a significant prison term, while others received varying sentences based on their roles in the crime [1][7]. - The legal proceedings emphasized the importance of accountability for the destruction of cultural heritage, with the court ensuring that penalties were proportionate to the crimes committed [6][7].

最新一期业绩显示，2025年一季报，公司实现营业收入1.92亿元，同比4.94%；净利润-115452483.95 元，同比-71.41%，销售毛利率27.36%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)26东方生物-8.13-8.870.7246.93亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052.4346.93亿1天益医疗-1742.06-2983.951.8622.20亿2澳华内 镜-602.36302.124.8363.48亿3诺唯赞-409.62-484.482.2587.66亿4爱朋医疗-362.84275.654.3729.77亿5博晖 创新-324.04514.213.4647.54亿6硕世生物-131.86-1926.851.1838.57亿7奥精医疗-125.28-183.621.6523.25亿 8睿昂基因-99.99-82.091.4212.94亿9康泰医学-84.67-71.543.0255.73亿10中红医疗-70.88-56.530.9049.26亿 11华大智造-59.73-53.004.11318.43亿 来源：金融界 5 ...

Group 1 - The core viewpoint of the news is that Dongfang Biological has shown a slight increase in stock price and has a low price-to-book ratio, indicating potential investment interest [1] - As of the first quarter of 2025, nine institutions hold shares in Dongfang Biological, with a total holding of 110.96 million shares valued at 2.87 billion yuan [1] - Dongfang Biological specializes in the research, production, and sales of in vitro diagnostic products, covering a full industry chain from raw materials to independent testing laboratories [1] Group 2 - The latest financial results for the first quarter of 2025 show that the company achieved revenue of 192 million yuan, a year-on-year increase of 4.94%, but reported a net loss of approximately 115.45 million yuan, a year-on-year decline of 71.41% [1] - The company's gross profit margin stands at 27.36% [1] - Dongfang Biological has accumulated a total of 639 authorized patents and software copyrights, with 268 domestic and 335 international patents [1]